REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 88.87% year-on-year.
Fairly Valued
The company’s latest PE is -2.37, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 45.28M shares, decreasing 7.13% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 62.96K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.53.